Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.70 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949265 | 0.93 | HCRTR2 (0.60) | HCRTR1HCRTR2HTR1ATSPOHSD17B10 | |
| SCHEMBL9948727 | 0.93 | HCRTR2 (0.60) | HCRTR1HCRTR2HTR1ATSPO | |
| SCHEMBL9949689 | 0.87 | HCRTR2 (0.91) | HCRTR1HCRTR2HSD17B10 | |
| SCHEMBL9948854 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2HTR1ATSPOCYP1A2 | |
| SCHEMBL9948971 | 0.79 | HCRTR1 (0.72) | HCRTR1HCRTR2HSD17B10 | |
| SCHEMBL9948694 | 0.78 | HCRTR1 (0.56) | HCRTR1HCRTR2HTR1ATSPO | |
| SCHEMBL2130838 | 0.77 | HCRTR2 (0.73) | HCRTR1HCRTR2HTR1ATSPO | |
| SCHEMBL9948671 | 0.76 | HCRTR1 (0.60) | HCRTR1HCRTR2CYP1A2CYP2C9TSHR | |
| SCHEMBL2132180 | 0.76 | HCRTR2 (0.72) | HCRTR1HCRTR2HTR1ATSPO | |
| SCHEMBL9948984 | 0.76 | HCRTR1 (0.72) | HCRTR1HCRTR2CYP1A2CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | claimed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | HCRTR1 593/4885HCRTR2 607/4885HTR1A 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.